title: Dendritic cell vaccination for patients with chronic myelogenous leukemia.
abstract: In this pilot study, we investigated the ability of autologous dendritic cells (DCs) pulsed ex vivo with leukemia-specific peptide to stimulate host antitumor immunity when administrated as a vaccine. Three patients with chronic myelogenous leukemia (CML) received three series of four administration of bcr-abl peptide-pulsed (1) blood DCs injected intravenously, (2) immature monocyte-derived DCs injected intradermally or (3) mature monocyte-derived DCs injected intradermally. Vaccination was well tolerated. No major toxicity occurred in any of the patients. In method (1), one patient developed peptide-specific cellular immune response with no clinical response. In method (2), one patient developed peptide-specific cellular immune response with no clinical response. In method (3), all patients developed peptide-specific cellular immune response with no clinical response. The clinical benefits of bcr-abl peptide-specific vaccination in CML remain to be determined. Further vaccine development is necessary to increase the clinical effect.
authors.affiliation: Department of Hematology and Oncology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Mie
authors.initials: M
authors.lastname: Nieda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Azuma
authors.forename: Shigeru
authors.initials: S
authors.lastname: Chiba
authors.forename: Takeo
authors.initials: T
authors.lastname: Juji
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Shibata
authors.forename: Hisamaru
authors.initials: H
authors.lastname: Hirai
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D005434:Flow Cytometry; D016044:Fusion Proteins, bcr-abl / Q000494:pharmacology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007111:Immunity, Cellular; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000096:biosynthesis; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology / Q000473:pathology; D010865:Pilot Projects; D012449:Safety; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D007371:Interferon-gamma; D016044:Fusion Proteins, bcr-abl